INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.
|Published (Last):||6 January 2014|
|PDF File Size:||13.59 Mb|
|ePub File Size:||11.53 Mb|
|Price:||Free* [*Free Regsitration Required]|
The liver is one of the main storage sites for iron, and some patients with chronic liver disease may have excessive iron storage. To restore hemoglobin and replenish iron stores due to blood loss. The first stage involves an inflammatory reaction at the site of injection which aids the passage of the drug into the lymphatic system. Ferritin and transferrin are also recommended monitoring parameters. These dimercaprol-iron complexes are more toxic than the metal alone, especially to the kidneys.
The following are generally accepted limits in the treatment of iron-deficient patients. A value of The stability of iron dextran in TPN solutions has not been well established. The contribution of iron to infectious processes is unclear, but iron dextran should not be administered during the acute phase of infectious renal disease manufacturer’s information.
Ankylosing spondylitis, asthma, atopy, rheumatoid arthritis, systemic lupus erythematosus SLE. DO NOT mix iron dextran with other medications. There are limits to the volume of iron dextran that may be injected IM per 24 hours based on patient age and weight; see dosage guidelines.
The extent of risk for anaphylactoid reactions to any specific iron dextran product is unknown and may vary among products. Serum iron, hemoglobin and hematocrit should be evaluated prior to iron therapy and at regular intervals during therapy.
Infants and Children 4 months and older weighing 10 to 15 kg.
Furthermore, concomitant use of angiotensin-converting enzyme inhibitors may increase the risk for serious reactions to iron dextran.
Cardiac disease, hypotension, intravenous administration.
To restore hemoglobin and replenish iron stores in iron-deficiency anemia due to causes other than blood loss. Subcutaneous injection results in slow absorption and staining of subcutaneous tissue. Adults, Adolescents, and Children weighing more than 15 kg. Patients should be monitored for signs and symptoms of anaphylactic-type reactions during all iron dextran administrations.
Iron crosses the placenta, and pregnancy increases iron-intake requirements. Iron dextran is not hemodialyzable. Concurrent use of deferiprone with iron supplements has not been studied. Adults, Adolescents, Children, and Infants 4 months and older.
Iron dextran (INFeD) | – A Hematology Oncology Wiki
The type of anemia and the underlying cause or causes should be determined before starting therapy with parenteral iron dextran. Major In general, oral mineral supplements should not be given since they may block the oral absorption of trientine. If supine, the patients should informationn in a lateral position and the injection should be into the upper-most part of the buttock.
If test dose uneventful, infuse the remainder of the total calculated dose see equation IV over 2 to infirmation hours. Iron dextran is contraindicated for use in patients with anemia not associated with iron deficiency.
If test dose uneventful, doses of 1. Some patients received epoetin in conjunction with parenteral iron. If test dose uneventful, give the remainder of prescribkng total dose as 25 mg of iron dextran per day IM or slow IV until the total lnformation dose see equation is given.
Both animal and human data indicate that the bulk of intravenous iron is sequestered in the reticuloendothelial system i. Patients with preexisting cardiac disease may have exacerbation of cardiovascular symptoms if adverse prexcribing occur following iron dextran administration.
Therapy with iron should generally be delayed until 24 hours after the cessation of dimercaprol therapy. Severe Deferoxamine chelates iron from ferritin or hemosiderin. Dilute the total calculated dose see Dosage in to mL of 0. Evaluate transferrin saturation and serum ferritin before and during epoetin alfa treatment. While iron is excreted into breast-milk, the iron content of breast milk is not readily affected by the iron content of the maternal diet or informtion maternal serum iron level.
Do not add therapeutic doses of iron dextran to total parenteral nutrition TPN solutions; iron dextran may destabilize the mixture or cause the cracking of the TPN emulsion.
Parenteral iron preparations e. In the study of infants with the gestational age of about 28 weeks, a dose of 0.
Iron dextran (INFeD)
Adult and Adolescent menstruating, premenopausal women. Therapeutically, it is typically illogical for a patient to receive both iron supplementation e. Before administering therapeutic doses by any route, a test dose of 25 mg 0. Periodic monitoring of serum ferritin levels may be helpful in recognizing a prescriging accumulation of iron resulting from impaired iron uptake from the reticuloendothelial system in patients with renal failure. Major Deferasirox chelates iron and is indicated as a treatment of iron toxicity or overdose.
Patients with hepatic disease should receive iron dextran with caution.